At the Healey Center, we are working hard to develop effective treatments for ALS and to provide people with ALS with access to potentially beneficial therapies.
In addition to clinical trials, this commitment includes providing access to investigational therapies for treatment through the Food and Drug Administration (FDA)-regulated Expanded Access Protocols (EAPs). Drugs available through EAPs are potential therapies that hold promise but have yet been proven to show benefit. EAP programs allow access to treatments for people who might not be eligible for clinical trials for a variety of reasons. Information gathered through patient participation in these studies can also provide important information to help bring treatments to market for everyone.